Transdermal iontophoresis. Part II: Peptide and protein delivery

被引:28
作者
Pillai, O
Nair, V
Poduri, R
Panchagnula, R
机构
[1] Natl Inst Pharmaceut Educ & Res, Dept Pharmaceut, Punjab 160062, India
[2] Natl Inst Pharmaceut Educ & Res, Dept Pharmacol & Toxicol, Punjab 160062, India
来源
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY | 1999年 / 21卷 / 03期
关键词
transdermal iontophoresis; peptides proteins; insulin; vasopressin; luteinizing hormone-releasing hormone; growth hormone releasing factor; thyrotropin releasing hormone;
D O I
10.1358/mf.1999.21.3.534833
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The advent of sophisticated biotechnological processes has generated an interest in peptide and protein pharmaceuticals. However the rapid developments in biotechnology are not matched by the developments in the delivery of these molecules. Presently, most of the peptides and proteins are delivered by parenteral route due to their poor oral bioavailability. The inherent discomforts associated with the parenteral therapy has prompted investigations into other nonparenteral routes and drug delivery techniques. Transdermal iontophoresis is one such technique showing good promise in the controlled and enhanced delivery of peptides and proteins. It offers noninvasive, continuous, pulsatile delivery as well as preprogrammed complex dosing regimens. Miniature battery powered and wearable patches for peptides and proteins are expected to be on the marker by the turn of this century. In continuation of our earlier review, this review explores the potential of transdermal iontophoresis for the delivery of peptides and proteins with the main focus on the suitability of the technique along with the factors to be considered in the design of this drug delivery system and its future prospects. (C) 1999 Prous Science. All rights reserved.
引用
收藏
页码:229 / 240
页数:12
相关论文
共 119 条
[61]   Iontophoresis of monomeric insulin analogues in vitro: effects of insulin charge and skin pretreatment [J].
Langkjaer, L ;
Brange, J ;
Grodsky, GM ;
Guy, RH .
JOURNAL OF CONTROLLED RELEASE, 1998, 51 (01) :47-56
[62]   EFFECT OF CURRENT MAGNITUDE AND DRUG CONCENTRATION ON IONTOPHORETIC DELIVERY OF OCTREOTIDE ACETATE (SANDOSTATIN(R)) IN THE RABBIT [J].
LAU, DTW ;
SHARKEY, JW ;
PETRYK, L ;
MANCUSO, FA ;
YU, ZL ;
TSE, FLS .
PHARMACEUTICAL RESEARCH, 1994, 11 (12) :1742-1746
[63]  
LEE V H L, 1987, Pharmaceutical Technology, V11, P38
[64]  
Lee VH, 1991, PEPTIDE PROTEIN DRUG, P691
[65]  
LEHR CM, 1994, CRIT REV THER DRUG, V11, P119
[66]   TRANSDERMAL IONTOPHORETIC DELIVERY OF ARGININE-VASOPRESSIN .1. PHYSICOCHEMICAL CONSIDERATIONS [J].
LELAWONGS, P ;
LIU, JC ;
SIDDIQUI, O ;
CHIEN, YW .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1989, 56 (01) :13-22
[67]   TRANSDERMAL IONTOPHORETIC DELIVERY OF ARGININE-VASOPRESSIN .2. EVALUATION OF ELECTRICAL AND OPERATIONAL FACTORS [J].
LELAWONGS, P ;
LIU, JC ;
CHIEN, YW .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1990, 61 (03) :179-188
[68]  
LI VHK, 1987, CONTROLLED DRUG DELI, P3
[69]  
LIU JC, 1988, INT J PHARM, V44, P197
[70]  
LLOYD LB, 1994, Patent No. 5328455